drugset
drugset / Trial / NCT02694536

A Study of Erlotinib in Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

NCT02694536 ↗

Phase 3 Completed 80 enrolled Hoffmann-La Roche
NaSingle-groupOpen-labelTreatment

Summary

This open-label, single-arm, multicenter trial is designed to evaluate the safety of erlotinib in combination with standard of care chemotherapy (gemcitabine) in participants with locally advanced, unresectable, or metastatic pancreatic cancer.

Timeline

Start
2006-08-01
Primary completion
2009-11-19
Completion
2009-11-19

Drugs

EvaluationDrugModalityDoseRoute
Subject Erlotinib Small molecule 100 mg Oral
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous

Indications

malignant pancreatic neoplasm